[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![_Investor_Feed_ Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1825090112713285632.png) Investor Feed [@_Investor_Feed_](/creator/twitter/_Investor_Feed_) on x 6154 followers
Created: 2025-07-25 14:40:10 UTC

RPG Life Sciences Q1 FY26 Update: Growth, ESG Wins & Strategic Moves 💊📈 | MCap XXXXXXXX Cr

- Domestic Formulations grew XXX% YoY in Q1 FY26, driven by new launches & salesforce productivity (>₹6 lakhs per rep).
- International Formulations declined XXX% YoY; APIs dropped XXXX% due to a fire incident.
- ICRA reaffirmed ratings: long-term A+ (stable), short-term A1, citing debt-free status & strong cash flows.
- Strategic focus: Expand immunosuppressant portfolio to ₹200+ crores, grow Naprosyn to ₹100+ crore brand.
- Capex of ~₹140 crores since FY22 for plant modernization (EU, TGA, PMDA approvals) & capacity expansion.
- ESG wins: XXXX% lower carbon emissions (FY25), XX% energy efficiency boost, zero landfill waste.
- Digital upgrades: e-QMS, IoT-based monitoring, cybersecurity measures.
- M&A strategy in play for growth synergies in target therapies & brands.

Complete Source:

Disc: Information provided in this tweet can be inaccurate, verify through the source before making any investment decision.

Preview 👇 (First X out of XX pages)

![](https://pbs.twimg.com/media/GwteVpxXMAEpLWE.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1948755158269059158/c:line.svg)

**Related Topics**
[longterm](/topic/longterm)
[productivity](/topic/productivity)
[esg](/topic/esg)
[investment](/topic/investment)

[Post Link](https://x.com/_Investor_Feed_/status/1948755158269059158)